Ann Arbor, Michigan, March 16, 2026
Zomedica Corp., a leading provider of veterinary diagnostic and therapeutic solutions, reported record financial performance for the fourth quarter and full year 2025, highlighting strong growth driven by increasing adoption of its animal health technologies. The company achieved $10.5 million in Q4 revenue, marking the first time quarterly revenue surpassed $10 million, and reported $32.0 million in full-year revenue, reflecting 17% year-over-year growth. This milestone represents the company’s 20th consecutive quarter of revenue growth, demonstrating sustained demand across its expanding portfolio of point-of-care diagnostics and therapeutic devices for companion and equine animals.
Strong Revenue Growth Driven by Diagnostics and Therapeutics
Zomedica’s performance was fueled by continued demand for its PulseVet® and Assisi® therapeutic device platforms, along with accelerating adoption of its TRUFORMA® diagnostic system, which provides rapid, point-of-care testing capabilities for veterinary clinics. The company reported 33% revenue growth in Q4, supported by 20% growth in consumable products, indicating a strong recurring revenue model. The therapeutic device segment generated $26.1 million, accounting for the majority of revenue, while the diagnostics segment contributed $2.8 million, reflecting ongoing expansion of diagnostic capabilities.
Additionally, the company’s newly introduced Development Services segment generated $3.1 million, opening new revenue streams through engineering services and contract manufacturing expertise. These results underscore Zomedica’s strategy to build an integrated animal healthcare ecosystem combining diagnostics, therapeutics, and development services.
Improved Margins and Operational Efficiency
Advertisement
Zomedica reported strong profitability metrics, with gross margins reaching 68% for the full year and 69% in Q4, reflecting efficient cost management and favorable product mix. The company also achieved a 7% reduction in operating expenses, driven by cost-control initiatives and improved operational efficiency. Cash burn was significantly reduced to $1.1 million in Q4, the lowest in the company’s history since commercialization, demonstrating progress toward financial sustainability and profitability goals.
Despite reporting a net loss of $81.9 million, largely due to non-cash impairment charges, adjusted financial metrics indicate improved operational performance. The company ended the year with a strong liquidity position of $53.3 million in cash and securities, providing flexibility to support future growth and innovation initiatives.
Expanding Global Reach and Innovation Pipeline
Zomedica continues to expand its global footprint, reporting 18% growth in international sales, driven by new distributor partnerships and increasing adoption of its technologies in global markets. The company is also investing in research and development, with $7.2 million allocated to advancing next-generation diagnostic and therapeutic solutions.
Its portfolio includes innovative products such as TRUVIEW® digital cytology, VETGuardian® monitoring systems, and VETIGEL® hemostatic gel, all designed to improve clinical outcomes and workflow efficiency in veterinary practices. By leveraging strategic acquisitions, product innovation, and international expansion, Zomedica aims to strengthen its position as a leader in the animal health industry, addressing a total addressable market exceeding $2 billion in the United States alone.
Source: Zomedica press release
